The objective of the present study is to develop a pharmaceutically stable, cost effective and quality improved robust formulation of Valsartan Immediate Release tablets. The aim of work is related to the formulation and evaluation of 10mg of dispersible tablet. Valsartan belongs to a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Total nine formulations were prepared by direct compression method in which the concentration of the superdisintegrants is varied to evaluate the effect on the disintegration time of valsartan mouth dissolving tablets. The superdisintegrants, involved in preparation are Sodium starch glycolate, Avicel PH 102, Low HPC. The prepared batches of tablets were evaluated for micromeritic...
Valsartan is a BCS class II antihypertensive drug whose bioavailability is dissolution rate limited....
Solid medicaments may be administered orally as powders, pills, cachets, capsules or tablets. These ...
Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the manage...
In the present study, design of oral immediate release tablets of Valsartan by direct compression te...
The present study has a design to evaluate the valsartan conventional tablets by using various binde...
ABSTRACT: The immediate release tablet of antihypertensive drug Valsartan were prepared and evaluate...
ABSTRACTObjective: The main objective present research work an attempt has been made to prepare fast...
The sustained release tablets were formulated by using the combination of various release retardant ...
The purpose of the present investigation was to develop and optimize bilayered sustained release mat...
Valsartan is a potent, orally active non peptide tetrazole derivative and selectively inhibits Angio...
The objective of the present study is optimization of valsartan SR floating tablet formulation by 22...
ABSTRACT Objective: The main objective of the current research is to formulate and evaluate solid d...
The goal of the current study is to produce a modified dose form of the hypertension drug Valsartan....
The objective of the present study is optimization of Valsartan tablet formulation employing βCD, St...
Both the Valsartan (VAL) and Olmesartan medoxomil (OLM) are widely prescribed anti-hypertensive agen...
Valsartan is a BCS class II antihypertensive drug whose bioavailability is dissolution rate limited....
Solid medicaments may be administered orally as powders, pills, cachets, capsules or tablets. These ...
Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the manage...
In the present study, design of oral immediate release tablets of Valsartan by direct compression te...
The present study has a design to evaluate the valsartan conventional tablets by using various binde...
ABSTRACT: The immediate release tablet of antihypertensive drug Valsartan were prepared and evaluate...
ABSTRACTObjective: The main objective present research work an attempt has been made to prepare fast...
The sustained release tablets were formulated by using the combination of various release retardant ...
The purpose of the present investigation was to develop and optimize bilayered sustained release mat...
Valsartan is a potent, orally active non peptide tetrazole derivative and selectively inhibits Angio...
The objective of the present study is optimization of valsartan SR floating tablet formulation by 22...
ABSTRACT Objective: The main objective of the current research is to formulate and evaluate solid d...
The goal of the current study is to produce a modified dose form of the hypertension drug Valsartan....
The objective of the present study is optimization of Valsartan tablet formulation employing βCD, St...
Both the Valsartan (VAL) and Olmesartan medoxomil (OLM) are widely prescribed anti-hypertensive agen...
Valsartan is a BCS class II antihypertensive drug whose bioavailability is dissolution rate limited....
Solid medicaments may be administered orally as powders, pills, cachets, capsules or tablets. These ...
Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the manage...